Selected Apelin Dose

PreclinicalSmall molecule

UUniversity Hospital, Basel, Switzerland

Selected Apelin Dose is one of 15 small molecule programs targeting Intravenous. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

IntravenousCompleted

IntravenousPreclinical

Completed

Competition

Competitive Landscape

23 competitors in Intravenous

#DrugCompanyPhaseTrials

Dilaudid

RRhodes Pharmaceuticals, L.P.

Approved

4 2

Ultram

WWim Janssens

Approved

1 3

Pitocin

RRetrophin

Phase 2

5 4

Magnesium SO4

HHospital de Base

Phase 3

1 5

Sodium Valproate

AstraZeneca

Phase 2

1 6

IV Thyroxin

RRambam Health Care Campus

Phase 3

1 7

Injectafer

AAmerican Regent, Inc.

Phase 3

1 8

Isordil

AstraZeneca

Preclinical

1 9

Esmeron

FFresenius Kabi USA, LLC

Preclinical

2 10

Nubain

AAultman Health Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intravenous1 trial

Effects of Intravenous [Pyr1]Apelin-13 on Healthy Volunteers With Artificially Induced SIAD

Completed·UUniversity Hospital, Basel, Switzerland·N/A·NCT06277336·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Selected Apelin Dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Selected Apelin Dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Selected Apelin Dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Basel, Switzerland company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Basel, Switzerland

Selected Apelin Dose

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Intravenous1 trial

References

Drug Info

Quick Facts

Related News